Trials / Completed
CompletedNCT05828472
A Study of Multiple Ascending Doses MY008211A in Healthy Adults
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Doses Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of MY008211A Tablets in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a single-center, randomized, double-blind, placebo-controlled, dose-escalation, and multiple-dose study to evaluate safety, tolerability, PK and PD of MY008211A Tablets in healthy subjects.
Detailed description
MY008211A Tablets, low/moderate/high dose orally, continually 7 days
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MY008211A tablets | MY008211A tablets, low/moderate/high dose orally, for 7 days |
| DRUG | MY008211A tablets matched placebo | MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days |
Timeline
- Start date
- 2023-01-10
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
- First posted
- 2023-04-25
- Last updated
- 2023-09-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05828472. Inclusion in this directory is not an endorsement.